- Home
- BRW vs DMAC Comparison
BRW vs DMAC Comparison
Compare BRW & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRW
- DMAC
- Stock Information
- Founded
- BRW 1987
- DMAC 2000
- Country
- BRW United States
- DMAC United States
- Employees
- BRW N/A
- DMAC N/A
- Industry
- BRW Trusts Except Educational Religious and Charitable
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- BRW Finance
- DMAC Health Care
- Exchange
- BRW Nasdaq
- DMAC Nasdaq
- Market Cap
- BRW 355.1M
- DMAC 310.1M
- IPO Year
- BRW N/A
- DMAC N/A
- Fundamental
- Price
- BRW $7.31
- DMAC $6.25
- Analyst Decision
- BRW
- DMAC Strong Buy
- Analyst Count
- BRW 0
- DMAC 3
- Target Price
- BRW N/A
- DMAC $12.33
- AVG Volume (30 Days)
- BRW 222.1K
- DMAC 271.0K
- Earning Date
- BRW 01-01-0001
- DMAC 11-12-2025
- Dividend Yield
- BRW 15.59%
- DMAC N/A
- EPS Growth
- BRW N/A
- DMAC N/A
- EPS
- BRW N/A
- DMAC N/A
- Revenue
- BRW N/A
- DMAC N/A
- Revenue This Year
- BRW N/A
- DMAC N/A
- Revenue Next Year
- BRW N/A
- DMAC N/A
- P/E Ratio
- BRW N/A
- DMAC N/A
- Revenue Growth
- BRW N/A
- DMAC N/A
- 52 Week Low
- BRW $7.15
- DMAC $3.19
- 52 Week High
- BRW $8.30
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- BRW 36.34
- DMAC 38.19
- Support Level
- BRW $7.25
- DMAC $6.64
- Resistance Level
- BRW $7.46
- DMAC $7.18
- Average True Range (ATR)
- BRW 0.09
- DMAC 0.28
- MACD
- BRW 0.02
- DMAC -0.06
- Stochastic Oscillator
- BRW 19.05
- DMAC 9.73
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.